Around 47 million people live with Alzheimer’s worldwide, this costs $800 billion every year and, so far, 100% of clinical trials attempting to find a curative treatment have failed.
Patients are treated 15 years too late due to the lack of an early diagnosis.
Animal models used to select drug candidates do not fully replicate the human disease.
Currently approved medications do not change the progression of the disease.
Drug development in the field of Alzheimer’s disease is certainly among the most challenging and has been suffering dramatic setback regardless of the strategy developed. For 30 years, we targeted a stage of the disease which was too late to restore the cognitive impairment.
We need to detect patients 15 to 20 years before the onset of these irreversible symptoms to find an effective treatment.
Combining machine learning and neuroscience, AgenT is developing specific blood biomarkers combinations for each stage of the disease. Our algorithm will allow us to detect patients during the silent phase of Alzheimer's and stratify them according to the disease progression.
AgenT diagnosis will pave the way for a personalized medicine to prevent Alzheimer's dementia.
Cofounder & CEO
Cofounder & CFO
IM2A, Pitié-Salpêtrière Hospital
CEO & CSO
Chief Medical Officer
Former President of the French Academy of Sciences
Founder & CEO
Head of the CMLA UMR 8536, ENS Paris-Saclay & CNRS
You can contact us with anything related to our company. We'll get in touch with you as soon as possible.
STATION F, Founders Program
5 Parvis Alan Turing
75013 Paris, France
Phone: +33 6 66 43 90 61